Literature DB >> 20650507

Hospital costs incurred by the Italian National Health Service for invasive cervical cancer.

Gabriella Ferrandina1, Andrea Marcellusi, Francesco Saverio Mennini, Marco Petrillo, Carlo Di Falco, Giovanni Scambia.   

Abstract

METHODS: A longitudinal, retrospective, cohort study was designed to assess the mean treatment cost of invasive cervical cancer, cross-linking clinical and administrative databases. The study was performed from the Italian NHS perspective. Costs were estimated using DRG charges. All patients with histological diagnosis of invasive cervical cancer admitted to Gynecologic Oncology centres of the Catholic University of the Sacred Heart between 2000 and 2007 were enrolled.
RESULTS: Overall, 351 patients (212 with LACC and 139 with ECC) were eligible for analysis. The mean direct medical cost by patient was € 22,200 ± 21,600 with a significantly higher burden for LACC compared with ECC patients (€ 28,696 ± 24,874 versus € 12,329 ± 8,726). Radical surgery accounted for € 6,851 ± 1,406, and € 7,709 ± 3,710 in ECC and LACC group, respectively; the resulting difference achieved a statistical significance. The extent of disease, disease progression/recurrence, and length of hospitalization confirmed their independent role as cost predictive factors.
CONCLUSIONS: The combined use of administrative and clinical databases allowed a feasible assessment of the mean cost induced by the invasive cervical cancer. Management of LACC patients was associated with higher costs due to the utilization of several therapeutic strategies and more frequent appearance of disease progression/recurrence.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20650507     DOI: 10.1016/j.ygyno.2010.06.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.

Authors:  Francesco Saverio Mennini; Andrea Marcellusi; Lara Gitto; Florenzo Iannone
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

2.  Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis.

Authors:  I Cromwell; Z Ferreira; L Smith; K van der Hoek; G Ogilvie; A Coldman; S J Peacock
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

Review 3.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

Review 4.  Health technology assessment on cervical cancer screening, 2000-2014.

Authors:  Betsy J Lahue; Eva Baginska; Sophia S Li; Monika Parisi
Journal:  Int J Technol Assess Health Care       Date:  2015-01       Impact factor: 2.188

5.  Medical Cost to Treat Cervical Cancer Patients at a Social Security Third Level Oncology Hospital in Mexico City

Authors:  Víctor Granados-García; Patricia Piña-Sánchez; Nancy Reynoso-Noveron; Yvonne N Flores; Filiberto Toledano-Toledano; Gloria Estrada-Gómez; Teresa Apresa-García; Arely A Briseño
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

6.  Economic burden of human papillomavirus-related diseases in Italy.

Authors:  Gianluca Baio; Alessandro Capone; Andrea Marcellusi; Francesco Saverio Mennini; Giampiero Favato
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

7.  The Bayesian model on human papillomavirus vaccination in Italy lacks transparency.

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Med Care       Date:  2013-04       Impact factor: 2.983

8.  Impact of HPV vaccination: health gains in the Italian female population.

Authors:  Andrea Marcellusi
Journal:  Popul Health Metr       Date:  2017-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.